The complex between the macrocyclic ligand DOTA and the metal gadolinium (Gd 3+ ) has been used as the contrast agent for the MRI T1 weighed imaging. Mono substitution on the tetraaza ring of DOTA ligand results in the formation of the two distinct complexes that are regioisomers of each other and they have different contrast efficiency as well as stability. These regioisomers are only separated by HPLC. With two bulky substituents on the tetraaza ring, it is expected to increase
INTRODUCTION

The use and limitation of DOTA in MRI imaging technique
MRI imaging has been widely used for the diagnosing purposes in the medical fields because this technique does not require the use of radioactive isotopes and provides high spatial resolution [1] [2] [3] . Many different scans and contrast levels can be applied until the normal and the abnormal parts can be observed [4] . Therefore, the role of contrast agents in MRI imaging is very important.
Depending on the texture of the examining area that the appropriate scan sequence is selected [4] .
For T1 weighed imaging, gadolinium based contrast agent (GBCA) is used very often. GCBA is a complex of lanthanide metal ion gadolinium (Gd 3+ .) The most famous ligand for GBCA is the macrocyclic DOTA [5] (figure 1.) The function GBCA is to interact with the water molecules in the examining area to reduce their protons' T1 time constants. Those time constants reflect the different relaxation of the protons in different environments and they are assigned with different color scales. Combining the location and the color scales, the MRI T1 weighed image is formed [6] [7]
The GBCA complex itself is safe for the human body.
However, if decomplexation happens, the free metal ion Gd 3+ , whose radius is 108pm, can displace the metal ion Ca 2+ , whose radius is 114pm. Ca 2+ participates in many biochemical processes of the cells in the human body.
Gd 3+ can act as a competitive inhibitor of Ca 2+ and thus, disturb these processes [8] . That is why there is a growing concern about increasing the stability and thus, the safety of GBCA. In order to make Gd 3+ favor staying in the complex, modification on the ligand structure is necessary. This research focuses on modifying the macrocyclic (or the tetraaza ring) component of DOTA ligand.
Mono-substitution results stimulated the study of di-substitution
In the past studies, adding a nitro benzyl group on the tetraaza ring of DOTA affects the ability to form complex with Gd 3+ of this new ligand (NB-DOTA.) [9] [10] Specifically, when NB-DOTA interact with Gd 3+ , a fixed ratio of two distinct complexes are formed [10] . These complexes are regioisomer of each other (figure 2.) Depending on the direction when Gd 3+ approaches the ligand that corner or side regioisomers will form [10] . These regioisomers have different geometry, stability and energy, and thus, they have different contrast efficiency as showed in table 1 [11] . The most important difference to notice between the two regioisomers is the water residence time (τ M ) which is inversely proportional to the water exchange rate since this parameter reflects the interaction between the GBCA and the water molecules. These regioisomers can only be separated by HPLC (figure 3.) [10] These fascinating results stimulated the further study on the effect of substitution on DOTA's tetraaza ring. Therefore, di-substitution became the subject in this study. If two benzyl substituents are placed on the tetraaza ring of DOTA, two trends are expected. First, in order to maintain the stability of the ring, the conformation having the least steric hindrance will be favored.
Secondly, the presence of the two bulky benzyl groups reduces the macrocyclic ring's mobility of the complex and thus, prevents the conversion between the isomer forms due to ring flipping. If these two trends are observed, they can support the hypothesis that di-substitution can control what type of regioisomers will be formed and thus, no additional steps to separate the side and corner regioisomers are needed since only one type will be formed. The three patterns will be studied and their expected dominating regioisomers are summarized in figure 4. For the pattern 2,8-S,S and 2,5-S,S, the benzyl groups are on the same plane so the only way to minimize steric hindrance is to favor conformation having them in the equatorial positions. Once the complex is formed, corner regioisomer is more favorable since it has less steric hindrance. For the case of pattern 2,9-S,S, both corner and side regioisomers are expected but the specific ratio cannot be predicted since the two benzyl groups are located on the different plane of the ring. This allows the macrocyclic ring of its complex to have more mobility comparing to the other patterns.
Developing synthesis strategy to control the desired di-substitution patterns
The synthesis of these di-substituted DOTA includes four main stages: dibenzyl polypeptide chain, dibenzyl tetra amine chain, dibenzyl tetraaza cyclododecane, and dibenzyl DOTA. From the pure simple amino acids and amine, the dibenzyl peptide chain is built by using the peptide synthesis techniques. Building the peptide chain is an important stage because it determines the position of the benzyl substituents on the tetraaza ring in the future. Cyclization in the third stage is necessary since the substituents need to be located on the tetraaza ring before the pendant arms are added.
However, once the tetraaza ring is closed, the substituents will more likely to be attacked the lone pairs of the nitrogen atoms. Those nitrogen spots must be saved for the pendant arms to create the desired DOTA derivative forms. Therefore, the position of the benzyl substituents must be defined on the precursors of the tetraaza ring. The retro synthesis plan for the three patterns are showed in the figure 5 below: Cyclization procedure is based on the method developed by Reed and Weisman [12] to synthesize cyclen. Figure 6 below summarizes the cyclization process of the pattern 2,9-S,S with R is the abbreviation of the benzyl group letting Boc-Phe-OSu reacts with ammonium then remove the Boc group and build the next bond.
The progress of pattern 2,9-S,S
The synthesis progress of pattern 2,9-S,S is summarized in figure 9 below: This pattern is easier to synthesize than the other ones. All the desired peptide bonds were built in one step. After removing the Boc protection group, the polypeptide was successfully reduced to the desired tetraamine chain. The tetraamine chain is not ready for the cyclization process yet since is still in the aqueous layer. The 1 H-NMR spectrum of the organic layer did not have the aromatic signal from the benzyl substituents. In addition, the signals from the solvent were much stronger than the examining compound's. The protons from the linear chain and the benzyl substituents of 2,9-S,S-dibenzyl tetraamine showed up in the 1 H-NMR spectrum of the aqueous layer. However, this spectrum also contains strong signal from the solvent MeOH. Therefore, the next step will be developing a HPLC method to purify 2,9-S,S dibenzyl tetraamine chain. The 1 H-NMR spectrum and the mass spectrum of this tetraamine chain are showed in figure 10 . The molecular weight of the target molecule is 326.25 amu. The results from running the mass spec in the positive mode (M+H + ) has a significant high peak of 327.25 and thus, confirmed the presence of 2,9-S,S-dibenzyl tetraamine chain in the aqueous layer. 
H-NMR spectrum (right) of 2,9-S,S dibenzyl tetraamine
The progress of pattern 2,5-S,S
The synthesis progress of pattern 2,5-S,S is summarized in figure 11 below: 
HOD Aromatic protons
MeOH
Protons on the chain
This pattern is still at the stage of making the polypeptide chain which is showed in the figure 12. The strategy is to build from the N terminal: one side of Ethylene diamine is covered with the Cbz protection and the other is left active to build the first peptide bond with Boc-Phenylalanine-OSu. However, after putting the Cbz in, the product needed to be separated from the matrix. In the first trial, the last NMR spectra did not confirm the presence of Ethylene diamine having one protected side. There might be not enough Ethylene diamine. In the contrary, the dry flash column chromatography in the second trial was necessary because there was still some unprotected Ethylene diamine (its present was confirmed when comparing TLC of fraction 2 with Ethylene diamine in MeOH.) The three fractions obtained from the column are still being analyzed. Specifically, when performing the TLC comparing with the solvent MeOH and the mixture of MeOH and Et2O, fraction 2 seems to contain the desired product because it had different retention factor than the solvent's. Fraction 1 had the retention factor no different than the solvent. By that time fraction 3 was not dried yet to run TLC. Therefore, fraction 2 must be analyzed first. A large amount of MeOH and Et2O was added in fraction 2 in attempt to separate the desired product through crystallization. The NMR spectra of crystal from fraction 2 and the original fraction 3 in DMSO have not been analyzed yet.
EXPERIMENTAL PROCEDURE
The four starting materials for the peptide synthesis in this project are Boc-Glycine-OSu (BocGly-OSu), L Phenylalanine-OBn (Phe-OBn), Boc-Phenylalanine-OSu (Boc-Phe-OSu), and Ethylene diamine. Another goal must be achieved is to see if it is possible to make the desired polypeptide chains with a minimum number of the pure, prepared and simple amino acids. All amino acids used in this experiment were purchased from TCI America. Ethylene diamine and the other chemicals were purchased from Sigma-Aldrich. The mass spectrometry analysis were performed by using the ThermoElectron LTQ-Orbitrap Discovery high resolution mass spectrometer with an Accela HPLC system. The H-NMR spectra were collected by using the Bruker 400 MHz Avance II and spectrometer with the default probe is 5 mm BBFO. The use of the corrosive Ethylene diamine, air sensitive and toxic chemicals TFA, BH3.THF, Benzyl In both trials, the first goal was to add a Cbz protection group on one end of Ethylene diamine
(figure 19)
In trial 1, an air free condition was obtained by using the pressure equalizing funnel drop. At 0 o C, Ethylene diamine was added in DCM (100mL), then Benzyl chloroformate was added and the mixture was stirred for 1 hour before the addition of H2O (15mL). After extracting and removing the solvent DCM from the organic layer, the product was dissolved in CDCl3 to run 1 H-NMR but it was not the desired molecule.
In trial 2, after Ethylene diamine and Benzyl chloroformate got mixing in the same condition in the trial 1, the mixture was stirred overnight. Cu(OH)2CuCO3 (14.5mmol) in H2O (20mL) was slowly added and stirred. When the pH was 12, the organic layer was extracted with DCM and dried. 1 H-NMR analysis in MeOD was performed. TLC comparing with Ethylene diamine was performed. Dry flash column chromatography was performed on the sample with the first wash was Et2O and three fractions in MeOH. When all fractions dried, TLC tests comparing with MeOH, mixture of MeOH (35%) and Et2O (65%), and Ethylene diamine were performed to find the fraction containing the most amount of the product. A significant larger amount of the solvent containing MeOH and Et2O (ratio 1:2) was added in the fraction 2. After one day, the solvent was decanted to collect the crystalized solid. 1 H-NMR in DMSO of the crystalized fraction 2 and the fraction 3 were performed. 
